Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Treatment-associated phenotype switching between 

 is a clinically relevant, reproducible, and bidirectional real-world phenomenon, new data suggest, and may need to be recognized in clinical settings to guide therapeutic adaptation in certain cases.

These findings resulted from a retrospective, multi-center, multinational observational study designed to evaluate treatment-associated phenotype switching in inflammatory 

 across 17 dermatology centers located across Spain, Portugal, Italy, Switzerland, Greece, and Canada. The team was led by Tiago Torres, MD, PhD, professor of dermatology at the Instituto de Ciências Biomédicas Abel Salazar, University of Porto.

Torres et al reviewed real-world clinical findings to characterize cases in which individuals who are being treated for atopic dermatitis or for psoriasis developed a persistent change in clinical morphology at the time they received systemic or biologic medication.

“While isolated case reports and small case series have described this entity, systematic real-world data on clinical characteristics, triggering therapies and management strategies remain limited,” Torres and coauthors wrote.

Torres et al noted their definition of a phenotype switch in clinical practice as one’s dermatologist noting the sustained emergence of features consistent with the opposite disease. For example, psoriasiform findings in individuals with atopic dermatitis, or eczematous shifts in those on a treatment for psoriasis. It would specifically be when such changes took place temporally in connection with systemic or biologic exposure and were significant enough to prompt a management shift.

A histopathology or molecular testing-confirmation was not required, the investigative team noted, reflecting routine clinical decision-making in real-world clinical settings. Those deemed eligible included subjects showing established psoriasis or atopic dermatitis diagnoses who had also subsequently developed a clinician-documented, persistent phenotype change deemed related to systemic or biologic therapy and leading to changes in therapeutic agents.

Torres and colleagues gathered various demographic data, characteristics related to disease, treatment histories, and outcomes across participating centers. Their analyses were mainly descriptive in nature, with continuous variables summarized via assessment of central tendency and dispersion. Additionally, the team reported categorical variables as frequencies and proportions.

Where they deemed comparisons appropriate, the investigators implemented chi-square or Fisher’s exact tests for categorical data. Student’s t-test or Mann–Whitney U testing was used for continuous variables, depending on distribution.

Findings on Treatment-Associated Phenotype Switching

148 subjects met the investigators’ inclusion criteria. Among these, 68.2% with psoriasis developed eczematous features over the course of their therapy (psoriasis-to-eczema phenotype switch). Meanwhile, Torres and coauthors found 31.8% of these 148 patients, those with atopic dermatitis specifically, developed psoriasiform manifestations while on treatment (atopic dermatitis-to-psoriasis switch).

Unique clinical patterns emerged between the patient cohorts. Those showing psoriasis-to-eczema transitions tended to be older and had an increased burden of cardiometabolic comorbidities. Atopic comorbid conditions, by contrasting, were more often noted among those in the atopic dermatitis-to-psoriasis patient cohort.

Torres et al further noted therapeutic exposure appeared to differ by direction of switch. Most of the cases of psoriasis-to-eczema took place in patients on interleukin (IL)-17 or IL-23 pathway inhibitors. Alternatively, atopic dermatitis-to-psoriasis switches were seen exclusively among those treated with biologics targeting type 2 inflammation. Most commonly, this was seen with dupilumab.

In all cases, treatment was shifted after the phenotype change emerged. Janus kinase (JAK) inhibitors were shown to be the most frequently selected therapeutic strategy across both directions of switching. Particularly high utilization in the psoriasis-to-eczema cohort was observed. Across the study population, modification of therapeutic agents were generally linked with substantial clinical improvement, regardless of phenotype direction.

Overall, Torres and colleagues’ results support treatment-associated phenotype switching between psoriasis and atopic dermatitis as a bidirectional and as a reproducible phenomenon seen in routine clinical practice settings. They suggest, instead of representing paradoxical disease induction, the pattern likely indicates underlying immune system plasticity impacted by targeted pathway inhibition.

“Prospective studies integrating longitudinal clinical assessment with histological and molecular profiling will be essential to identify predictors of phenotype switching and to inform precision therapeutic approaches,” they concluded.

Torres T, Valenti M, Prajapati V, et al. Treatment-associated phenotype switching between psoriasis and atopic dermatitis. J Eur Acad Dermatol Venereol. 2026; 00: 1–9. 

Al-Janabi A, Foulkes AC, Warren RB, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1440-1448. doi: 10.1111/jdv.16246. Epub 2020 Feb 27. PMID: 31997406.

Articles

Treatment-associated phenotype switching between psoriasis and atopic dermatitis emerges as a consistent, bidirectional real-world phenomenon with implications for therapeutic strategy. In a retrospective multinational cohort across 17 dermatology centers, 148 patients developed persistent clinician-documented morphology consistent with the opposite disease temporally linked to systemic/biologic exposure and prompting treatment change. Switching patterns differed by patient profiles and biologic class exposure: psoriasis-to-eczema switches predominated with IL-17/IL-23 inhibitors, whereas atopic dermatitis-to-psoriasis switches clustered with type 2–targeting biologics, especially dupilumab. Treatment modification—often to JAK inhibitors—typically improved outcomes.

Treatment-associated phenotype switching between psoriasis and atopic dermatitis was noted to be reproducible and bidirectional in real-world clinical settings.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psoriasis-Atopic Dermatitis Phenotype Switching: New Real-World Data

Payam Dehghani, MD, is an associate professor of cardiology at the University of Saskatchewan and co-founder of Prairie Vascular Research, Inc.

COVID-19 Amplifies 1-Year STEMI Mortality Following Hospitalization

A new sub-study of the North American COVID-19 Myocardial Infarction (NACMI) Registry has shown that patients with COVID-19 and 

ST-elevation myocardial infarction (STEMI)

 continued to display higher mortality than pre-pandemic after hospital discharge.

These data were presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions in Montreal, Canada, by Payam Dehghani, MD, associate professor of cardiology at the University of Saskatchewan and co-founder of Prairie Vascular Research, Inc. Following the conclusion of the conference, the editorial team at 

 spoke with Dehghani in an exclusive interview to learn more about the data.

“We know that if you have a heart attack and you have COVID-19, you’re much more likely to die in hospital,” Dehghani told 

. “We published on that back in 2020 and 2021, that is not a surprise to anyone. What we don’t know is, if you survive hospitalization, for the remainder of your time outside the hospital, does your mortality look any different compared to people who have not had COVID-19?”

The NACMI Registry was designed as a prospective, investigator-initiated, multi-center observational registry enrolling confirmed COVID-19 patients and persons under investigation (PUIs) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the electrocardiogram with clinical suspicion of myocardial ischemia. These patients were enrolled from April 2020 to June 2021. Demographic information, descriptors at presentation with STEMI, and clinical outcomes were captured by the registry.

Patients aged ≥18 years with ST-segment elevation in ≥2 contiguous leads, a clinical correlate of myocardial ischemia, and confirmed COVID-19 infection, were eligible for enrollment. Those without available vital status were excluded, as were those with a “do not resuscitate” status or multiple futility markers on admission. The study’s primary outcome was in-hospital all-cause mortality.

A total of 474 patients with COVID-19 and STEMI were enrolled in the registry – 49 were excluded due to incomplete data or comfort care measures, leaving 425 patients for the study. The majority of patients were men (72%) aged 56-75 years and were more likely to be of minority ethnicity (21% Hispanic, 18% Black, 7% Asian) than White (46%).

Among these patients, 118 (28%) died in the hospital. Of the variables present at the time of diagnosis, including respiratory rate of >35 breaths/min, cardiogenic shock, oxygen saturation <93%, age of >55 years, infiltrates on chest x-ray, kidney disease, diabetes, and dyspnea, were assigned a weighted integer. In-hospital mortality increased exponentially with increasing integer risk scores.

The current sub-study included a total of 623 patients who were COVID-19 positive, along with 694 who were COVID-19 negative and a matched control cohort of 1041 patients collected from data recorded before COVID-19. Among the COVID-19 positive patients, 1-year mortality was 45% compared to 27% in the COVID-19 negative arm and 11% in the matched control arm (

 <.001). Most deaths occurred during index hospitalization (86%), with a median time to death of 27 days (interquartile range [IQR] 6, 343). Of the patients who survived index hospitalization, 1-year mortality rates were 12% in the COVID-19 positive arm, 9.6% in the COVID-19 negative arm, and 5.3% in the matched control arm (

Ultimately, Dehghani and colleagues noted that the high mortality among patients with COVID-19 and STEMI was driven predominately by deaths during the index hospitalization. Of those who survived to hospital discharge, mortality rates remained higher than pre-pandemic controls. The team determined that this difference reflects a need for intervention beyond the acute phase.

“Time is muscle. We’ve known this all along, but we forget about it, both for patient education programs and maybe even at hospitals,” Dehghani said. “Heart attack rates don’t drop – in fact, they probably go up during influenza and pandemics. I think we need to amplify that message, and I think our systems of care need to be made aware of that.”

Editors’ Note: Dehghani reports no relevant disclosures.

Dehghani P. North American COVID-19 Myocardial Infarction (NACMI) Registry: One-Year Follow-Up. Presented at the SCAI 2026 Scientific Sessions, Montreal, Canada. April 23-25, 2026.

Dehghani P, Schmidt CW, Garcia S, Okeson B, Grines CL, Singh A, Patel RAG, Wiley J, Htun WW, Nayak KR, Alraies MC, Ghasemzadeh N, Davidson LJ, Acharya D, Stone J, Alyousef T, Case BC, Dai X, Hafiz AM, Madan M, Jaffer FA, Shavadia JS, Garberich R, Bagai A, Singh J, Aronow HD, Mercado N, Henry TD. North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital Mortality. J Soc Cardiovasc Angiogr Interv. 2022 Sep-Oct;1(5):100404. 

Videos

Payam Dehghani, MD, discusses his sub-study of the NACMI registry, following patients with COVID-19 and STEMI who survived to hospital discharge.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Physician and CEO, Chicago Allergy Center, and board director at American Lung Association

Practicing critical care pulmonologist, Managing Director of Health Innovation at Manatt, medical analyst for NBC News and MSNBC, affiliate faculty at the University of Washington's Institute for Health Metrics and Evaluation, commissioned officer (Major) in the United States Air Force Medical Reserve Corps, and board member of the American Lung Association

ALA State of the Air 2026: Clinician Action

The American Lung Association (ALA)'s 2026 State of the Air report documents a continued and in some measures worsening picture of air quality across the United States. The 27th edition of the annual assessment finds that 44% of Americans — 152.3 million people — live in counties that received failing grades for unhealthy ozone or fine particulate matter (PM2.5) levels, with nearly 4 million more people breathing unhealthy ozone compared with the prior year's report.¹ Failing ozone grades now cover 219 counties across 36 states, the broadest distribution since 2016.¹ The report attributes the trend in part to the compounding influence of climate change on ozone formation conditions, as well as to wildfire smoke events with expanding geographic footprints.¹

Children represent both the most exposed and the most physiologically vulnerable population in these findings. Some 33.5 million children — 46% of those under 18 — live in counties that failed at least one air quality measure, and 7.3 million live in communities failing all 3.¹ Developing lungs are uniquely susceptible to the effects of chronic pollution: children breathe proportionally more air for their body size than adults, spend more time outdoors, and face cumulative developmental consequences from exposure during periods of active lung growth. Hispanic and Latino children bear a disproportionate share of this burden, with the report finding they are approximately 3 times more likely than white children to live in a community that fails all three pollutant grades.¹ Bakersfield, California — which carries both chronic ozone and particle pollution burdens — ranked as the metropolitan area with the worst year-round particle pollution for the seventh consecutive year.¹

 spoke with Juanita Mora, MD, allergist-immunologist at Chicago Allergy Center and attending physician at Advocate Illinois Masonic Medical Center, and Vin Gupta, MD, MPA, pulmonologist and Managing Director of Health Innovation at Manatt, also of Virginia Mason Medical Center and MS NOW news, about what the 2026 findings mean for patients and for the field. Mora, a medical expert for the ALA, focused on the clinical stakes for children with developing lungs and called on clinicians to engage legislators on maintaining EPA funding and clean air protections. Gupta, an ALA board member, framed the report's value primarily as a public education opportunity, while expressing skepticism that the current administration's regulatory posture will shift in response to it — and arguing that the more effective path forward lies in communicating about air quality in non-divisive, fact-centered terms capable of reaching a broader public over time.

“How do we smartly animate people? I think a lot less of it is stoking division and creating conflict, and it's more about persuasion through just informing… I do think there's a majority of this country, when given facts in a calm, rational, apolitical way, will be able to at least receive that message,” Gupta said.

The full 2026 State of the Air report is available at lung.org/SOTA.

American Lung Association. State of the Air 2026. Published April 21, 2026. 

Drs. Vin Gupta and Juanita Mora discuss the recent report and how it should inform clinician actions.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Strategic Alliance Partnership

Managing GI, Liver Safety Signals With Volixibat in PSC, With Kris Kowdley, MD

With a potential New Drug Application (NDA) submission to the 

 on the horizon for Mirum Pharmaceuticals’ volixibat, 

sat down with lead VISTAS phase 2b study investigator, Kris Kowdley, MD, for a clinical perspective on its safety profile in adults with primary sclerosing 

 for Part 1 where Kowdley explains VISTA’s findings!

Managing GI Adverse Events in PSC and IBD

“It’s well known that IBAT inhibitors are associated with loose stools and sometimes diarrhea. It’s also recognized that these symptoms can be managed in the majority of patients,” explained Kowdley, director at Liver Institute Northwest and senior scientific advisor and medical director at Velocity Clinical Research. “In the patient with PSC and concomitant IBD, the clinician has to be more thorough and more careful in evaluating whether this could potentially be a superinfection with Clostridium difficile, whether this could be a flare of underlying IBD, or whether it’s just a symptom associated with IBAT therapy.”

Volixibat Meets Primary Endpoint in VISTAS

Recently, volixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, 

, a statistically significant placebo-adjusted reduction in itch severity over 28 weeks.

PSC remains a disease with a major unmet need, given there are no FDA-approved therapies specifically indicated to manage pruritus in PSC, which affects up to 50% to 60% of patients. Pruritus is commonly managed with off-label approaches such as bile acid sequestrants, rifampin, opioid antagonists, and selective serotonin reuptake inhibitors, but tolerability and efficacy are variable.³

Understanding IBAT Inhibition in Cholestatic Pruritus

IBAT, also called apical sodium-dependent bile acid transporter (ASBT), is a protein predominantly located in the terminal ileum, serving as the main transporter mediating the ileal uptake of conjugated bile acids and their return to the liver through enterohepatic circulation.

FDA Approves Linerixibat (Lynavoy) As First Treatment for 

Linerixibat, an IBAT inhibitor, became the

 specifically indicated for cholestatic pruritus in primary biliary cholangitis (PBC). The approval was based on the phase 3 GLISTEN trial, which showed improvement in pruritus and itch-related sleep disruption as early as 2 weeks and over 24 weeks, compared with placebo.

Other notable safety findings included elevations in liver laboratory parameters, including alanine aminotransferase (ALT) and bilirubin.

“We will be educating clinicians about how to observe patients carefully for any symptoms that might be more concerning, such as jaundice, fatigue, etc., and in that case we would obviously intervene and measure their liver tests and evaluate them clinically,” Kowdley said. “Other than that, we have not seen much in the way of safety concerns, and so far adverse events leading to discontinuation of therapy have been gratifyingly low.”

The topline results were announced on May 4, 2026, along with tentative plans to submit an NDA for volixibat in the second half of 2026.

Editor’s Note: Kowdley reports relevant disclosures with Akero, 89Bio, Boehringer Ingelheim, Boston Pharmaceuticals, Genfit, Gilead, GlaxoSmithKline, Intercept, Madrigal, Mirum, and others.

Brooks A. Volixibat Improves Pruritus in Phase 2b PSC Trial. HCPLive. Published May 4, 2026. Accessed May 14, 2026. 

https://www.hcplive.com/view/volixibat-improves-pruritus-in-phase-2b-psc-trial-with-gi-and-liver-safety-signa

Mirum Pharmaceuticals. Mirum Pharmaceuticals announces primary endpoint met in VISTAS study of volixibat in patients with primary sclerosing cholangitis. Business Wire. May 4, 2026. Accessed May 4, 2026. 

https://www.businesswire.com/news/home/20260504069726/en/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-VISTAS-Study-of-Volixibat-in-Patients-with-Primary-Sclerosing-Cholangitis

Bowlus CL, Lim JK, Lindor KD. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. 

https://doi.org/10.1016/j.cgh.2019.07.011

GI and liver safety signals for clinicians to know from the VISTAS evaluating volixibat in PSC-associated pruritus.

Hepatology

Volixibat's Safety Profile Explained for PSC, With Kris Kowdley

Desmond Schatz, MD, is a professor and medical director of the Diabetes Institute and the director of the Clinical Research Center in the CTSI at the University of Florida.

Population-Based Screening for T1D: Benefits and Barriers, With Desmond Schatz, MD

 is feasible, but gaps in education and training handicap its real-world implementation.

, Desmond Schatz, MD, professor and medical director of the Diabetes Institute and director of the Clinical Research Center in the CTSI at the University of Florida, highlights the critical importance of early and frequent T1D screening, given the volume of patients potentially at risk of developing the disease.

“1 in 20 relatives of patients with type 1 diabetes are at risk of developing the disease,” Schatz told 

 in an exclusive interview. “It’s really important that we can screen. We have the tools available, we’ve learned a lot about the natural history of the disease, and as such, we can offer screening to really all relatives of patients with type 1 diabetes, as well as those who are at risk.”

The American Diabetes Association (ADA) released an updated version of its Standards of Care in Diabetes in 2026, expanding on a 2025 recommendation for autoantibody-based screenings in at-risk individuals. The updated document further expands on this procedure, with an emphasis on family history of T1D or known elevated genetic risk as a red flag for clinicians.

The guidelines recommend that screening should be offered to any of these patients, but actual data reflect that ≤90% of cases have no established familial connection. Schatz and colleagues suggest that clinicians maintain a “high index of suspicion” for T1D. The team suggests, based on existing analyses, that population-based screening, rather than symptom-based, could increase the number of children diagnosed by roughly 60%. These initiatives have been implemented in the UK and Italy, although broader implementation is held back by multiple uncertainties.

Schatz and colleagues highlight the critical need for educational initiatives, given that many have insufficient knowledge of the disease and its potential complications. Another study showed that 16% of individuals diagnosed with T1D before the age of 18 were initially diagnosed with a different condition – this misdiagnosis was then associated with an 18% increased risk of diabetic ketoacidosis (DKA).

Additionally, gaps in training are reflected in the clinic – T1D screening has not been widely integrated into medical education. Schatz highlights the need for hands-on training, informational guides, interactive case-based activities, and so on to alleviate this shortcoming.

Another key shortcoming in T1D testing flagged by the team is a lack of familiarity with the available options, resulting in substantial inertia. Schatz and colleagues stated that primary care clinicians should be made aware of available autoantibody screenings so that they can ensure patients receive accurate and on-time screenings before symptoms manifest.

Commercial laboratories (LabCorp, Quest Diagnostics)

Enable Biosciences – offers at-home testing kits, partnerships with Breakthrough T1D

TrialNet – offers screening of relatives and clinical studies

Autoimmunity Screening for Kids (ASK) – pediatric research study screening US residents ≥1 year with or without T1D history

Screening Central – various screening options & free clinician follow-up

Ultimately, Schatz and colleagues emphasize the need for enhanced training, education, and awareness around both the need for T1D screening and the various organizations that can provide it to patients. They encourage primary care physicians and pediatricians to discuss T1D risk with patients and families, emphasizing the need for attentive monitoring and early screening.

“You’ve got to get to know the family,” Schatz said. “You’ve got to understand that each family is very different, and you have to work on establishing a relationship with a family. It’s a very detailed discussion, and at this point in time it should only be done in specialized centers because, even if they did have the time, I think pediatricians are not educated enough to know the nuances of the disease.”

Editors’ Note: Schatz reports serving on the board of the Diabetes Leadership Council.

Bowser AD, Schatz D. Type 1 diabetes screening in pediatrics: Putting guidelines into practice. Pediatrics Open Science. 2026;2(2):1-3. 

American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S27-S49. 

Schatz highlights the current limitations to a broader integration of T1D screening and suggests methods to circumvent these blockages.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Scott A. Wilke, MD, PhD, an assistant professor of psychiatry and the Penske Family Chair in Neuromodulation at UCLA Health.

In a Q&A, psychiatrist Scott Wilke, MD, explains how accelerated TMS protocols are reshaping depression care and may help tailor treatment to specific neural circuits.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Accelerated TMS Moves Toward Circuit-Based Depression Treatment

Investigators released long-term data on long-term bimekizumab use in psoriasis suggest, demonstrating sustained efficacy through 4 years.

Long-Term Durability of Bimekizumab Over 4 Years Highlighted in Psoriasis 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA has cleared the EndoTool IV Cloud for hospital IV insulin dosing support, expanding Glooko’s inpatient platform via the 510(k) pathway.

FDA News

FDA Clears EndoTool IV Cloud for Inpatient IV Insulin Dosing Support

This episode spotlights a recent publication by Ashkar and colleagues—co-authored by Jennifer Geremia—surveying prescribing practices for EPI across a broad cross-section of healthcare professionals.

Video Series

Evidence in Practice: What a New Prescribing Survey Reveals About EPI Care Gaps

How experts track Wilson disease symptoms, fine-tune chelation or zinc, and use tremor, dystonia therapies to protect quality of life.

Multidisciplinary Symptom Management and Strategies for Modifying Therapy in Wilson Disease

Monitoring Treatment Response and Preventing Copper Insufficiency in Wilson Disease

Clinicians reveal where pancreatic care falls apart—diagnosis delays, post-discharge gaps, lost oncology follow-up—and how to fix handoffs fast.

Bridging the Gaps: Care Transitions and Breakdowns in EPI

Pugazhendi Vijayaraman, MD, is the director of cardiology at Geisinger Wilkes-Barre.

Pugazhendhi Vijayaraman, MD, discusses his recent presentation of the final results of LEADR LBBAP, simplifying the lead placement problems faced by earlier models.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

LEADR LBBAP: Sternum Lead Implantation Safe for CRT-D or ICD Patients

Investigators used the Global Burden of Disease (GBD) 2023 database to summarize skin cancers’ epidemiology, patterns, and projections to 2050.

Global Skin Cancer Patterns From 1990 - 2023, Projections to 2050 Identified

Kowdley explains phase 2b VISTAS data suggesting volixibat rapidly reduced PSC-associated pruritus in adults with limited treatment options.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Latest News

Psoriasis-Atopic Dermatitis Phenotype Switching: New Real-World Data

COVID-19 Amplifies 1-Year STEMI Mortality Following Hospitalization

ALA State of the Air 2026: Clinician Action

Volixibat's Safety Profile Explained for PSC, With Kris Kowdley

Population-Based Screening for T1D: Benefits and Barriers, With Desmond Schatz, MD